Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Enpp-1-IN-12 (compound 43), an orally active and potent inhibitor of ecto-nucleotide pyrophosphatase/phosphodiesterases 1 (ENPP1) with a K i of 41 nM, exhibits anti-tumor activity [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 10-14 weeks | $ 1,520.00 | |
50 mg | 10-14 weeks | $ 1,980.00 | |
100 mg | 10-14 weeks | $ 2,500.00 |
Description | Enpp-1-IN-12 (compound 43), an orally active and potent inhibitor of ecto-nucleotide pyrophosphatase/phosphodiesterases 1 (ENPP1) with a K i of 41 nM, exhibits anti-tumor activity [1]. |
In vitro | Enpp-1-IN-12 (5 μM) demonstrates a half-life exceeding 120 minutes and an intrinsic clearance rate below 11.55 μL/min/million cells in human hepatocytes, while manifesting a half-life of 61.88 minutes and a clearance rate of 22.4 μL/min/million cells within mouse hepatocytes [1]. |
In vivo | Enpp-1-IN-12, at a dosage of 100 mg/kg administered orally, effectively inhibits tumor growth in a syngeneic murine model for lung cancer derived from LLC1 cells. At a lower dose of 10 mg/kg, the compound demonstrates moderate oral bioavailability (F=45.1%) with a half-life of 1.04 hours and a peak concentration (C max) of 303.10 ng/mL in healthy female BALB/c mice. When administered intravenously at 1 mg/kg, Enpp-1-IN-12 shows a half-life of 0.76 hours, a peak concentration of 308.64 ng/mL, and a clearance rate of 73.22 mL/min/kg in the same mouse model. |
Molecular Weight | 373.43 |
Formula | C17H19N5O3S |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Enpp-1-IN-12 inhibitor inhibit